Instant Alert: Johnson & Johnson backs out negotiations to buy Actelion Pharmaceuticals

MANAGE SUBSCRIPTIONS   |   UNSUBSCRIBE   |   VIEW ONLINE   Johnson & Johnson backs out negotiations to buy Actelion Pharmaceuticals by Ismail Shakil on Dec 13, 2016, 7:46 PM Advertisement Dec 13 (Reuters) - U.S. healthcare company Johnson & Johnson said on Tuesday it has ended discussions with Actelion regarding a potential deal with Europe's largest biotech firm. J&J said it was not able to reach an agreement that it believed would create adequate value for its shareholders. J&J said in November that it was in preliminary talks with Actelion about a takeover of the firm, then valued at about $20 billion.   Share the latest business news with your network:    Email sent to:   |   Manage your email preferences   |   Unsubscribe Terms of Service   |   Privacy Policy Business Insider. 150 Fifth Avenue, New York, NY 10011